Abstract

A method of treating non-melanoma skin cancer or a precancerous skin condition in a patient is provided. The method includes applying to a lesion on the patient a topical composition including 5-aminolevulinic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient; incubating the topical composition on the lesion; and illuminating the lesion with a blue light source.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61N 5/06 - Radiation therapy using light
• A61P 17/00 - Drugs for dermatological disorders
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure is directed to polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Hd8HdRR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 487/04 - Ortho-condensed systems
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof. Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/75 - Polymers of hydrocarbons of ethene
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61N 5/06 - Radiation therapy using light
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations

Goods & Services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Goods & Services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Goods & Services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Goods & Services

(1) Medical device for crushing applicators containing pharmaceutical preparations

Goods & Services

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders

Abstract

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• C07D 487/04 - Ortho-condensed systems
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants

Abstract

The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

yl)-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 487/04 - Ortho-condensed systems

Abstract

A method of treating non-melanoma skin cancer in a patient in need thereof is provided. The method includes administering a hedgehog pathway inhibitor to the patient and applying to a region of skin on the patient, a topical composition comprising 5-aminolevulinic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The method further includes incubating the topical composition on the region of skin; and illuminating the region of skin with a light source at an irradiance density of 20 mW/cm2.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61N 5/067 - Radiation therapy using light using laser light

Goods & Services

(1) Photodynamic and photodetection pharmaceutical preparations for the treatment of dermatological conditions (2) Medical devices and apparatuses for photodynamic therapy and photodetection for use in conjunction with pharmaceutical products and preparations (1) Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare (2) Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders; providing medical information for physicians, pharmacists, and patients in the field of dermatology; providing medical information regarding pharmaceutical products for the treatment and prevention dermatology, and skin diseases and disorders

Abstract

D-serine.

IPC Classes  ?

• C07C 227/32 - Preparation of optical isomers by stereospecific synthesis
• C07D 263/04 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Abstract

The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 487/04 - Ortho-condensed systems

Abstract

Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods and topical compositions for use in photodynamic therapy are disclosed, in which the topical composition is applied to the affected area of a patient for a period in the range of about 15 minutes to about 10 hours.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Goods & Services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases

Goods & Services

(1) Business administration of pharmacy reimbursement programs and services; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies (2) Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status and related information for others (3) Distribution services, namely, delivery of pharmaceutical products. (4) Patient support and assistance in connection with pharmaceutical services, namely, providing medical information about pharmaceuticals

Abstract

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

A method of treating a JAK-inhibition-responsive condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of a compound represented by structural formulas (I) or (II), as described herein, or a pharmaceutically acceptable salt thereof. A method of treating a JAK-inhibition-responsive condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of a compound represented by structural formulas (I) or (II), as described herein, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 309/65 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Goods & Services

Medical device for crushing applicators containing pharmaceutical preparations

Goods & Services

(1) Non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions.

Goods & Services

Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare Photodynamic and photodetection pharmaceutical preparations for the treatment of dermatological conditions Medical devices and apparatuses for photodynamic therapy and photodetection for use in conjunction with pharmaceutical products and preparations Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders; providing medical information for physicians, pharmacists, and patients in the field of dermatology; providing medical information regarding pharmaceutical products for the treatment and prevention dermatology, and skin diseases and disorders

Goods & Services

Promoting public awareness of the importance of dermatology, treatment of dermatological diseases and disorders, skin care and healthcare Providing an online website featuring medical information in the field of dermatology; providing medical information through websites in the field of dermatology, skin disorders and treatments thereof; providing medical information regarding pharmaceutical products for the treatment and prevention of dermatology, and skin diseases and disorders; providing medical information to patients relating to prevention and treatment of dermatological disorders

Goods & Services

Business administration of pharmacy reimbursement programs and services; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status and related information for others Distribution services, namely, delivery of pharmaceutical products Patient support and assistance in connection with pharmaceutical services, namely, providing medical information about pharmaceuticals

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, gastrointestinal, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for the treatment of hair loss disorders; pharmaceutical preparations, namely, medicated dermatological preparations; pharmaceutical preparations for the treatment of alopecia areata, atopic dermatitis, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Goods & Services

non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions

Abstract

A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

(1) Anti-inflammatory pharmaceutical preparations; dermatological pharmaceutical preparations for the treatment of dermatitis, skin pigmentation diseases and psoriasis; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Goods & Services

(1) Analgesics; antacids; anti-cancer preparations; antibiotics; anticoagulants; anticonvulsants; antidepressants; antidiabetic preparations; antifungal preparations; antihypertensives; antiseptic preparations; antivirals; calcium channel blockers; corticosteroids; laxatives; nausea treatment preparations; pharmaceutical preparations for controlling cholesterol; pharmaceutical preparations for maintaining normal blood pressure and heart function; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of iron deficiency and anemia in humans; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of muscle spasms, tremors and pain; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations namely, anti-inflammatories; psychiatric pharmaceutical preparations for the prevention and treatment of mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; steroids; tumor suppressing agents

Goods & Services

(1) Downloadable mobile applications for patients and parents to enter patient daily journal entries, track daily skincare routines, upload photos, and find a dermatologist; downloadable mobile applications to provide healthy tips in the field of acne and skincare

Goods & Services

(1) Providing a website and online social media featuring educational information in the field of the diagnosis, prevention, and treatment of skin conditions, including acne

Abstract

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof. Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/20 - Pills, lozenges or tablets
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 487/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

Certain aspects of the present invention are directed to improved processes for preparing enantiomerically enriched intermediates for the synthesis of ruxolitinib and deuterated forms of ruxolitinib. Certain aspects are also directed to deuterated intermediates useful in the synthesis of deuterated forms of ruxolitinib. Certain aspects are also directed to reaction mixtures for preparing enantiomerically enriched intermediates useful in the synthesis of ruxolitinib and deuterated forms of ruxolitinib.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• B01J 31/40 - Regeneration or reactivation

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/75 - Polymers of hydrocarbons of ethene
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61N 5/06 - Radiation therapy using light
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations

Goods & Services

(1) Printed materials, namely, patient guides, consent forms and pregnancy prevention checklists, providing information relating to the treatment of dermatological conditions (1) Educational services to patients in the treatment of dermatological conditions (2) Medical services for the treatment of dermatological conditions

Abstract

Improved processes and intermediates for preparing ruxolitinib, deuterated analogs of ruxolitinib, and other JAK inhibitors are disclosed.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Goods & Services

Providing a website featuring educational information in the field to medical diagnosis, prevention, and treatment of skin conditions, particularly, acne

Goods & Services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne

Abstract

A method of performing photodynamic therapy is provided. The method includes applying, to the skin of a patient, a topical composition. The topical composition includes 5-aminolevulinic acid (ALA) hydrochloride, and a vehicle comprising at least one chelating agent to enhance accumulation of protoporphyrin IX (PpIX) in the skin. The method further includes incubating the topical composition, and following incubation, applying, to the skin, heat from a heat source for at least a first time period.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

Abstract

Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods and topical compositions for use in photodynamic therapy are disclosed, in which the topical composition is applied to the affected area of a patient for a period in the range of about 15 minutes to about 10 hours.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Goods & Services

(1) Medical device for treating and diagnosing dermatological conditions.

Abstract

Dermal neurofibroma, in particular Neurofibromatosis Type I (NF1) leads to progressive tumor proliferation with no known mechanism to inhibit growth. The present invention relates to the use of photodynamic therapy (PDT) for attenuating tumor growth in NF1 patients. More particularly the invention provides a method of treating dermal neurofibroma comprising topically applying a pharmaceutical composition comprising a photosensitizer to the affected area of a patient, incubating the affected area, and irradiating the affected area with a light of suitable wavelength as per the photosensitizer used, wherein the treatment is characterized by inhibiting the progression of tumor growth and/or reduction in tumor size and/or increased mortality rate of the neurofibroma cell.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61P 35/00 - Antineoplastic agents

Abstract

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/75 - Polymers of hydrocarbons of ethene

Abstract

This present invention and its embodiments relates to methods for reducing pain during photodynamic therapy of actinic keratosis. The present invention also relates to methods of treating actinic keratosis with reduced pain during photodynamic therapy of actinic keratosis.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention is directed to methods of treating diseases and disorders of the skin (e.g., acne) with heat-enabled photodynamic therapy (HEPT).

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 17/10 - Anti-acne agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/107 - Emulsions
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Abstract

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Abstract

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 309/65 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Goods & Services

Medical device for treating and diagnosing dermatological conditions

Abstract

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.

IPC Classes  ?

• C07C 227/32 - Preparation of optical isomers by stereospecific synthesis
• C07D 263/04 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Abstract

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/18 - Sulfonamides
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
• C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group

Abstract

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Goods & Services

(1) Printed materials, namely patient guides, consent forms and pregnancy prevention checklists, providing information relating to the treatment of dermatological conditions, none of the foregoing in the nature of a magazine in the fields of nursing and healthcare. (1) Educational services to patients in the treatment of dermatological conditions (2) Medical services for the treatment of dermatological conditions

Abstract

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/75 - Polymers of hydrocarbons of ethene

Abstract

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

IPC Classes  ?

• C07C 59/115 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
• C07C 69/67 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/225 - Polycarboxylic acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 59/125 - Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
• C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
• C07C 69/708 - Ethers

Abstract

Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This invention relates to novel α-tocotrienol quinones of Formula I: (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering Vitamin E.

IPC Classes  ?

• C07C 50/06 - Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/75 - Polymers of hydrocarbons of ethene

Goods & Services

Pharmaceutical preparations for the treatment of autoimmune, gastrointestinal, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for the treatment of hair loss disorders; pharmaceutical preparations, namely, medicated dermatological preparations; pharmaceutical preparations for the treatment of alopecia areata, atopic dermatitis, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Abstract

An applicator for dispensing a solution having two or more components includes a hollow body having a head provided at one end of the hollow body for dispersion of the solution and a breaking mechanism attached to the hollow body. The breaking mechanism includes at least one projection extendable into an interior of the hollow body. The applicator further includes a plurality of ampoules placed in the interior of the hollow body. The plurality of ampoules contains the two or more components. Upon activation of the breaking mechanism, the at least one projection applies a force to the plurality of ampoules such that the plurality of ampoules break and release the two or more components to form the solution.

IPC Classes  ?

• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61J 1/06 - Ampoules or cartridges
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61N 5/06 - Radiation therapy using light
• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe

Abstract

A method of administering 5-aminolevulinic acid (ALA) to a patient uses an adjustable illuminator for photodynamically diagnosing or treating a surface and which includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group

Goods & Services

Medical device for crushing applicators containing pharmaceutical preparations

Goods & Services

Medical device for crushing applicators containing pharmaceutical preparations

Goods & Services

Non-laser blue light producing device to be used in conjunction with pharmaceutical products or preparations to produce a therapeutic or diagnostic treatment of dermatological conditions

Abstract

An illuminator for photodynamically diagnosing or treating a surface includes a plurality of panels. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of panels. The plurality of light sources are configured to irradiate the surface with substantially uniform intensity visible light. The illuminator also includes a heat source configured to emit heat to a patient. The heat increases the generation of a photoactivatable agent and thus shortens the time needed to complete photodynamic therapy.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Goods & Services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Abstract

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Goods & Services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Goods & Services

(1) Acne medications; acne treatment preparations; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne.

Goods & Services

Pharmaceutical and medicinal preparation for treatment of dermatological conditions

Goods & Services

Business administration of pharmacy reimbursement programs and co-pay support programs; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status in the field of medical and pharmaceutical insurance and related information for others; financial administration of pharmacy reimbursement program and co-pay support programs

Goods & Services

Business administration of pharmacy reimbursement programs and co-pay support programs; retail pharmacy services; mail order pharmacy services; online retail pharmacy services; pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies Patient benefits programs in connection with pharmaceutical services, namely, providing financial assistance for disadvantaged persons for pharmaceuticals; Financial administration of pharmacy reimbursement programs and services; Patient support and assistance in connection with pharmaceutical services, namely, providing information about eligibility for financial assistance provided through patient benefits programs; Insurance services in the form of insurance verification services and prior authorization services, namely, verifying Medicaid, Medicare, and commercial insurance eligibility status in the field of medical and pharmaceutical insurance and related information for others; financial administration of pharmacy reimbursement program and co-pay support programs

Abstract

1 receptor agonist that also has NMDA antagonist activity.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• C07D 221/28 - Morphinans
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07D 471/08 - Bridged systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Goods & Services

(1) Kits for the preparation of radiolabeled pharmaceuticals, namely, radioactive compounds used for diagnostic or therapeutic purposes for use in in vivo diagnostic imaging procedures; Radioactive pharmaceutical agents, namely, pharmaceutical drugs containing radioactive isotopes for use in in vivo diagnostic imaging

Goods & Services

Kits for the preparation of radiolabeled pharmaceuticals for use in in vivo diagnostic imaging procedures; Radioactive pharmaceutical agents for use in in vivo diagnostic imaging

Abstract

The present invention in one embodiment provides a method of treating Leber's hereditary optic neuropathy, comprising administering to a subject in need of such treatment a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

IPC Classes  ?

• C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/75 - Polymers of hydrocarbons of ethene

Abstract

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/75 - Polymers of hydrocarbons of ethene

Abstract

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/20 - Pills, lozenges or tablets
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.

IPC Classes  ?

• C07C 323/22 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid

Abstract

This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• C07D 221/28 - Morphinans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• C07D 471/08 - Bridged systems
• A61P 25/16 - Anti-Parkinson drugs
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/08 - AntiepilepticsAnticonvulsants
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

IPC Classes  ?

• C07C 50/28 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• C07D 473/06 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3